Regeneron Pharmaceuticals | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
AbbVie USD 10.71B 458M 2024-12
Agios Pharmaceuticals USD 7.64M 1.83M 2025-03
Alnylam Pharmaceuticals USD 523.15M 32.8M 2025-03
Amgen USD 5.54B 430M 2025-03
Astellas Pharma JPY 382.44B 36.45B 2025-03
AstraZeneca USD 11.35B 819M 2025-03
Biogen USD 1.87B 44.1M 2024-12
BioMarin Pharmaceutical USD 593.59M 17.59M 2025-03
Bristol-Myers Squibb USD 8.18B 947M 2025-03
Eli Lilly USD 10.5B 624.7M 2025-03
Gilead Sciences USD 5.99B 17M 2024-12
GlaxoSmithKline GBP 5.59B 34M 2025-03
Incyte USD 985.09M 111.22M 2025-03
Ionis Pharmaceuticals USD 130.15M 92.6M 2025-03
J&J USD 14.6B 816M 2025-03
Kyowa Hakko Kirin JPY 80.14B 15.15B 2025-03
Merck USD 12.77B 849M 2025-03
Moderna USD 17M 403M 2025-03
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
Novartis USD 10.23B 294M 2024-12
Novartis USD 10.24B 313M 2024-12
Pfizer USD 11.12B 987M 2025-03
Regeneron Pharmaceuticals USD 2.56B 659.4M 2025-03
Roche Holding CHF 11.69B 48M 2024-12
Sanofi EUR 5.36B 4.71B 2024-12
Sarepta Therapeutics USD 607.29M 81.18M 2025-03
Teva Pharmaceutical Industries USD 1.91B 206M 2025-03
Ultragenyx Pharmaceutical USD 110.63M 37.35M 2025-03
United Therapeutics USD 701.9M 41.9M 2025-03
Vertex Pharmaceuticals USD 2.49B 109.3M 2024-12



Regeneron Pharmaceuticals Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.